Dyne Therapeutics Competitors

Dyne Therapeutics (NASDAQ:DYN) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 80.7% of ChemoCentryx shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 9.3% of ChemoCentryx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and ChemoCentryx, as provided by MarketBeat.

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. ChemoCentryx has a consensus price target of $80.7778, suggesting a potential upside of 63.48%. Given Dyne Therapeutics' higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than ChemoCentryx.

Earnings and Valuation

This table compares Dyne Therapeutics and ChemoCentryx's top-line revenue, earnings per share and valuation.

Dyne Therapeutics has higher earnings, but lower revenue than ChemoCentryx.

Profitability

This table compares Dyne Therapeutics and ChemoCentryx's net margins, return on equity and return on assets.

Summary

ChemoCentryx beats Dyne Therapeutics on 5 of the 9 factors compared between the two stocks.

Dyne Therapeutics (NASDAQ:DYN) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 95.3% of Nektar Therapeutics shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and Nektar Therapeutics, as provided by MarketBeat.

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. Nektar Therapeutics has a consensus price target of $25.2857, suggesting a potential upside of 35.73%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than Nektar Therapeutics.

Earnings and Valuation

This table compares Dyne Therapeutics and Nektar Therapeutics' top-line revenue, earnings per share and valuation.

Dyne Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics.

Profitability

This table compares Dyne Therapeutics and Nektar Therapeutics' net margins, return on equity and return on assets.

Summary

Dyne Therapeutics beats Nektar Therapeutics on 6 of the 9 factors compared between the two stocks.

Dyne Therapeutics (NASDAQ:DYN) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 7.0% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and PTC Therapeutics, as provided by MarketBeat.

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. PTC Therapeutics has a consensus price target of $64.90, suggesting a potential upside of 36.34%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than PTC Therapeutics.

Earnings and Valuation

This table compares Dyne Therapeutics and PTC Therapeutics' top-line revenue, earnings per share and valuation.

Dyne Therapeutics has higher earnings, but lower revenue than PTC Therapeutics.

Profitability

This table compares Dyne Therapeutics and PTC Therapeutics' net margins, return on equity and return on assets.

Summary

Dyne Therapeutics beats PTC Therapeutics on 6 of the 9 factors compared between the two stocks.

Dyne Therapeutics (NASDAQ:DYN) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and Apellis Pharmaceuticals, as provided by MarketBeat.

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. Apellis Pharmaceuticals has a consensus price target of $124.6154, suggesting a potential upside of 199.84%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Dyne Therapeutics.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Dyne Therapeutics and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Dyne Therapeutics and Apellis Pharmaceuticals' top-line revenue, earnings per share and valuation.

Summary

Apellis Pharmaceuticals beats Dyne Therapeutics on 5 of the 8 factors compared between the two stocks.

Insmed (NASDAQ:INSM) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Insmed and Dyne Therapeutics, as provided by MarketBeat.com.

Insmed presently has a consensus target price of $53.8571, suggesting a potential upside of 69.90%. Dyne Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 104.48%. Given Dyne Therapeutics' higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Insmed.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. 4.6% of Insmed shares are held by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Insmed and Dyne Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Insmed and Dyne Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Dyne Therapeutics has lower revenue, but higher earnings than Insmed.

Summary

Dyne Therapeutics beats Insmed on 5 of the 8 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and Dyne Therapeutics, as provided by MarketBeat.com.

ACADIA Pharmaceuticals presently has a consensus target price of $32.7647, suggesting a potential upside of 60.69%. Dyne Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 104.48%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than ACADIA Pharmaceuticals.

Insider and Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 59.4% of Dyne Therapeutics shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ACADIA Pharmaceuticals and Dyne Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares ACADIA Pharmaceuticals and Dyne Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Dyne Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals.

Summary

Dyne Therapeutics beats ACADIA Pharmaceuticals on 5 of the 9 factors compared between the two stocks.